Antibody–Drug Conjugates (ADCs) Derived from
... combined results indicate that ADC activity is highly dependent upon the conjugation sites and suggest that optimal conjugation sites are likely to be different for each antibody. Recombinant methods using non-natural amino acids to enable site-specific conjugation have also been reported. For example ...
... combined results indicate that ADC activity is highly dependent upon the conjugation sites and suggest that optimal conjugation sites are likely to be different for each antibody. Recombinant methods using non-natural amino acids to enable site-specific conjugation have also been reported. For example ...
Breast Chemotherapy Regimen v 3.5 Oct 2015
... Monitor cardiac function (ECG/ECHO/MUGA) of all patients baseline and at 3, 6, 9, 12 months during treatment and at 6, 12 and 24 months following cessation after treatment. ...
... Monitor cardiac function (ECG/ECHO/MUGA) of all patients baseline and at 3, 6, 9, 12 months during treatment and at 6, 12 and 24 months following cessation after treatment. ...
November 2014 - Positive Recommendations
... November 2014 agenda. The PBAC considered that this was due to the different trial data available for bevacizumab for each indication. On the basis of direct evidence presented by the submission, for patients treated with aflibercept there would be: approximately a 10.01 letter gain in best correc ...
... November 2014 agenda. The PBAC considered that this was due to the different trial data available for bevacizumab for each indication. On the basis of direct evidence presented by the submission, for patients treated with aflibercept there would be: approximately a 10.01 letter gain in best correc ...
Infusion reactions associated with use of biologic
... including infusion reactions, overlapping with other chemotherapeutics have been reported. The infusion reactions generally occur with the first dose [4]. The infusion reactions with monoclonal antibodies are mostly mild but if not managed appropriately, they may prove life threatening. Infusional t ...
... including infusion reactions, overlapping with other chemotherapeutics have been reported. The infusion reactions generally occur with the first dose [4]. The infusion reactions with monoclonal antibodies are mostly mild but if not managed appropriately, they may prove life threatening. Infusional t ...
Estimating changes in overall survival using progression
... new drug for metastatic breast or colorectal cancer will add to overall survival times given that the number of months the drug adds to progression-free survival times relative to a standard drug is roughly already known. Methods: A literature search was conducted over Medline for randomized control ...
... new drug for metastatic breast or colorectal cancer will add to overall survival times given that the number of months the drug adds to progression-free survival times relative to a standard drug is roughly already known. Methods: A literature search was conducted over Medline for randomized control ...
Experimental Treatments for Leptomeningeal Metastases From
... Lymphoma Kinase in Lung Cancer: The CNS is a frequent site of relapse among patients with ALK-rearranged NSCLC who have been treated with crizotinib.24 The poor penetration of crizotinib to the brain (“pharmacokinetic relapse”), rather than cellular resistance, has been suspected as the mechanism of ...
... Lymphoma Kinase in Lung Cancer: The CNS is a frequent site of relapse among patients with ALK-rearranged NSCLC who have been treated with crizotinib.24 The poor penetration of crizotinib to the brain (“pharmacokinetic relapse”), rather than cellular resistance, has been suspected as the mechanism of ...
Next-Generation Cancer Therapeutics
... Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions being considered by the Company may not proceed as contemplated, as well as risks inherent in additional ...
... Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions being considered by the Company may not proceed as contemplated, as well as risks inherent in additional ...
Cartilage And Nutriceutical Update
... Cartilade® in various advanced cancers 1995. Information on these current FDA-approved studies are not in the public realm. The protocol produced by Cartilage Technologies, Inc., is being undertaken by Michael Rothkopf. M.D., and an oncology group headed by Stewart Leitner, M.D., of St Barnabas Hosp ...
... Cartilade® in various advanced cancers 1995. Information on these current FDA-approved studies are not in the public realm. The protocol produced by Cartilage Technologies, Inc., is being undertaken by Michael Rothkopf. M.D., and an oncology group headed by Stewart Leitner, M.D., of St Barnabas Hosp ...
The New Generation of Targeted Therapies for
... the development of irreversible tyrosine kinase inhibitors such as CI-1033 and EKB-569 was, in part, the higher concentrations of erbB inhibitors required to continuously block erbB1 phosphorylation in intact cells where intracellular adenosine triphosphate (ATP) concentrations are higher. The appro ...
... the development of irreversible tyrosine kinase inhibitors such as CI-1033 and EKB-569 was, in part, the higher concentrations of erbB inhibitors required to continuously block erbB1 phosphorylation in intact cells where intracellular adenosine triphosphate (ATP) concentrations are higher. The appro ...
Angiogenesis of Breast Cancer
... cell lines.49 In another preclinical study, exposure to trastuzumab significantly decreased VEGF in HER-2overexpressing cells.50 In-vivo experiments have shown reduction in xenograft volume using a combination of trastuzumab and bevacizumab compared with singleagent control.50 In a cohort of 611 pati ...
... cell lines.49 In another preclinical study, exposure to trastuzumab significantly decreased VEGF in HER-2overexpressing cells.50 In-vivo experiments have shown reduction in xenograft volume using a combination of trastuzumab and bevacizumab compared with singleagent control.50 In a cohort of 611 pati ...
Tykerb - Novartis Pharmaceuticals Corporation
... Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. HER2-Positive Metastatic Breast Canc ...
... Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. HER2-Positive Metastatic Breast Canc ...
View PDF
... in chromosome. This kind of gene therapy could also be used in treating other genetically related diseases. The overall process of integration of virus into cellular DNA, leading to the delivery of desired genetic Material is called as integration. This process sometimes may or may not alter host’s ...
... in chromosome. This kind of gene therapy could also be used in treating other genetically related diseases. The overall process of integration of virus into cellular DNA, leading to the delivery of desired genetic Material is called as integration. This process sometimes may or may not alter host’s ...
Hutchison MediPharma R&D briefing Friday, 17 October 2014 9:30am to 1pm
... - Clinical benefit beyond first generation • Greater inhibition of primary pharmacology / target • Inadequate inhibition of primary target typically limits efficacy (e.g. Crizotinib) • Lack of potency means many compounds have high dose and poor PK (e.g. Lapatanib) • Precise mechanism of action stil ...
... - Clinical benefit beyond first generation • Greater inhibition of primary pharmacology / target • Inadequate inhibition of primary target typically limits efficacy (e.g. Crizotinib) • Lack of potency means many compounds have high dose and poor PK (e.g. Lapatanib) • Precise mechanism of action stil ...
News Release Puma Biotechnology Reports First Quarter 2016
... (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and i ...
... (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and i ...
Antibody-Drug Conjugates (ADCs) – Biotherapeutic bullets
... the mid 1990s (1). According to market analysis, the outlook remains strong for at least 35 new drug approvals per year until 2016 (2). The next blockbuster drug discoveries may well emerge from a class of targeted cell based immunotherapeutics called antibody-drug conjugates (ADCs). These are being ...
... the mid 1990s (1). According to market analysis, the outlook remains strong for at least 35 new drug approvals per year until 2016 (2). The next blockbuster drug discoveries may well emerge from a class of targeted cell based immunotherapeutics called antibody-drug conjugates (ADCs). These are being ...
AusPAR: Trastuzumab emtansine - Therapeutic Goods Administration
... submitted in support of this application have been evaluated in accordance with the Australian legislation, pharmacopoeial standards and relevant technical guidelines adopted by the TGA. The issue of free maytasinoid levels during storage was raised by the Pharmaceutical Subcommittee (PSC) who suppo ...
... submitted in support of this application have been evaluated in accordance with the Australian legislation, pharmacopoeial standards and relevant technical guidelines adopted by the TGA. The issue of free maytasinoid levels during storage was raised by the Pharmaceutical Subcommittee (PSC) who suppo ...
A New Therapeutic Option for Metastatic Breast Cancer
... chemotherapeutic options for treatment of MBC include taxanes, anthracyclines, vinca alkaloids, gemcitabine, capecitabine, ixabepilone, and newer formulations of old drugs such as cationic liposomal anthracyclines and nanoparticle‑albumin‑bound paclitaxel. Taxanes have serious dose‑limiting toxiciti ...
... chemotherapeutic options for treatment of MBC include taxanes, anthracyclines, vinca alkaloids, gemcitabine, capecitabine, ixabepilone, and newer formulations of old drugs such as cationic liposomal anthracyclines and nanoparticle‑albumin‑bound paclitaxel. Taxanes have serious dose‑limiting toxiciti ...
Banking on a Big Biobetters Bonanza Will China Use its Capabilities
... A team from the Beijing Institute of Biotechnology has attempted to bypass this issue by inserting protease cleavage sites or disulfide linkages between HSA and IFN-α2b.18 They found that fusion proteins with intermediate release rates had the most balanced PK and PD. In particular, they showed that ...
... A team from the Beijing Institute of Biotechnology has attempted to bypass this issue by inserting protease cleavage sites or disulfide linkages between HSA and IFN-α2b.18 They found that fusion proteins with intermediate release rates had the most balanced PK and PD. In particular, they showed that ...
Metformin inhibits proliferation and promotes apoptosis of HER2
... A previous study [9] confirmed that metformin inhibited the proliferation of triple-negative breast cancer cells by inhibiting the activation of EGFR pathway and promoting cell apoptosis. Vazquez and colleagues [14] found that metformin could prevent the proliferation of HER2 positive breast cancer ...
... A previous study [9] confirmed that metformin inhibited the proliferation of triple-negative breast cancer cells by inhibiting the activation of EGFR pathway and promoting cell apoptosis. Vazquez and colleagues [14] found that metformin could prevent the proliferation of HER2 positive breast cancer ...
Timely Recognition of Cardiovascular Toxicity by Anticancer
... the action mechanisms of the mAb and lapatinib [1]. In fact, lapatinib would be able to induce cardiac protection by stimulation of AMP-activated protein kinase (AMPK), a key regulator of energy metabolism in the heart, while trastuzumab does not [15]. Imatinib and Other Abelson Kinase (Abl) Inhibit ...
... the action mechanisms of the mAb and lapatinib [1]. In fact, lapatinib would be able to induce cardiac protection by stimulation of AMP-activated protein kinase (AMPK), a key regulator of energy metabolism in the heart, while trastuzumab does not [15]. Imatinib and Other Abelson Kinase (Abl) Inhibit ...
Inertly labeled monoclonal antibodies for PET and optical imaging
... region makes it possible to initiate the further immune response that will remove the antigen from the system. Development of monoclonal antibodies From the early 1900s on, many researchers tried to find a method to develop antibodies directed against one specific antigen, i.e. monoclonal antibodies ...
... region makes it possible to initiate the further immune response that will remove the antigen from the system. Development of monoclonal antibodies From the early 1900s on, many researchers tried to find a method to develop antibodies directed against one specific antigen, i.e. monoclonal antibodies ...
Articles January 22, 2013 – February 11, 2013 Breast Cancer
... are more expensive, "but less error prone than the commonly used CT scan." The Intermountain team also concluded that complex, expensive-to-treat diseases such as cancer are a large part of the problem. ...
... are more expensive, "but less error prone than the commonly used CT scan." The Intermountain team also concluded that complex, expensive-to-treat diseases such as cancer are a large part of the problem. ...
Down-regulation of HER-2 Expression in Human Breast Cancer Cell
... of the cytocidal effect of CPA just exists in combination chemotherapies, yielding great benefits in estrogen receptor negative breast cancer (4,18). The molecular mechanism underlying the effectiveness in combination chemotherapy has been reported as bcl-2 (8), p53 (2), and HER-2. HER-2 is the most ...
... of the cytocidal effect of CPA just exists in combination chemotherapies, yielding great benefits in estrogen receptor negative breast cancer (4,18). The molecular mechanism underlying the effectiveness in combination chemotherapy has been reported as bcl-2 (8), p53 (2), and HER-2. HER-2 is the most ...
Targeting cell signaling pathways for drug discovery
... tissues or cell types (e.g., diabetes and immunoinflammatory disorders). The search for cancer drugs has traditionally focused on the molecular signaling pathways that go berserk in cancer cells. These signaling pathways rely heavily on the action of over 500 protein kinases whose dysregulation has ...
... tissues or cell types (e.g., diabetes and immunoinflammatory disorders). The search for cancer drugs has traditionally focused on the molecular signaling pathways that go berserk in cancer cells. These signaling pathways rely heavily on the action of over 500 protein kinases whose dysregulation has ...
Issues in Biotechnology
... lymphosarcoma was given 10 consecutive doses of nitrogen mustard, a 10th of a milligram to a milligram per kilogram of body weight, roughly 2.5 times what became the standard dose. Within two days a softening of the tumor masses was noted. By the end of treatment the tumors disappeared. A month late ...
... lymphosarcoma was given 10 consecutive doses of nitrogen mustard, a 10th of a milligram to a milligram per kilogram of body weight, roughly 2.5 times what became the standard dose. Within two days a softening of the tumor masses was noted. By the end of treatment the tumors disappeared. A month late ...